Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
Prostatic Neoplasms|Bone Density
DRUG: Zolderonic acid (Zometa)
Bone mineral density of lumber spine, 12 months after administration of zolderonic acid|Bone mineral density of femoral neck, 12 months after administration of zolderonic acid
Change in serum creatinine, calcium, phosphate and alkaline phosphatase, From time of enrollment to 3 months after the last intervention|Change in creatinine clearance, From time of enrollment to 3 months after the last intervention
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.